Patents by Inventor Tirtha Chakraborty

Tirtha Chakraborty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250140342
    Abstract: Some aspects provide for techniques for genotyping cells in a biological sample. In some embodiments, the techniques include: obtaining single cell DNA sequence (scDNA-seq) data for a plurality of droplets; and genotyping the cells using the scDNA-seq data, the genotyping comprising determining for each droplet, a genotype for a locus of a respective genome of at least one cell associated with the droplet, the determining comprising: identifying, from among the plurality of droplets, a first set of droplets associated with cells that are homozygous at the locus; identifying, from among the plurality of droplets not in the first set of droplets, a second set of droplets associated with more than two alleles at the locus; and identifying, from among the plurality of droplets not in the first or second sets of droplets, a third set of droplets associated with cells that are heterozygous at the locus.
    Type: Application
    Filed: October 18, 2024
    Publication date: May 1, 2025
    Applicant: VOR BIOPHARMA INC.
    Inventors: Matthew HaoJon Ung, Ruijia Wang, Gary Huanying Ge, Tirtha Chakraborty
  • Publication number: 20250122534
    Abstract: Provided herein are methods of making genetically engineered cells having a plurality of modifications (e.g., insertions or deletions), cells and cell populations produced by said methods, methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: August 2, 2022
    Publication date: April 17, 2025
    Applicant: VOR BIOPHARMA INC.
    Inventors: Tirtha Chakraborty, Elizabeth Paik, Michelle Lin, Juliana Ferrucio
  • Publication number: 20250082755
    Abstract: Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: July 29, 2022
    Publication date: March 13, 2025
    Applicant: VOR BIOPHARMA INC.
    Inventors: Rebecca Moeller, Tirtha Chakraborty, Julian Scherer
  • Patent number: 12246030
    Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: March 11, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
  • Publication number: 20250041349
    Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.
    Type: Application
    Filed: October 28, 2024
    Publication date: February 6, 2025
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ewelina Morawa, Tirtha Chakraborty, Ante Sven Lundberg, Tony Ho, Laura Sandler, Brenda Eustace, Jerome Rossert, Robert Kauffman
  • Publication number: 20240417755
    Abstract: Provided herein are fusion polypeptides comprising a Cpf1 domain lacking nuclease activity and an endonuclease domain. Also provided herein are fusion polypeptides further comprising a genomic modification domain, which in some embodiments is a base editor, such as a deaminase. Also provided herein are methods involving contacting the fusion polypeptides with a gRNA to form a genetic editing system directed to a target site sequence in the genome of a cell.
    Type: Application
    Filed: September 27, 2022
    Publication date: December 19, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Elizabeth Paik, Dane Hazelbaker, Tirtha Chakraborty
  • Publication number: 20240408234
    Abstract: When a cancer patient is administered an anti-cancer therapy targeting a lineage specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and/or CD312 (EMR2)), e.g., in the form of an immunotherapeutic agent, the therapy can deplete not only cancer cells expressing the lineage-specific cell-surface antigen, but also noncancerous cells expressing the lineage-specific cell-surface antigen in an “on-target, off tumor” effect. This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in an endogenous lineage-specific cell-surface antigen (e.g., CD33 (Siglec-3), CLL-1, CD123, CD327 (Siglec-6), and/or CD312 (EMR2)) gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
    Type: Application
    Filed: September 14, 2022
    Publication date: December 12, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Alejandra Falla, Elizabeth Paik, Dane Hazelbaker, Tirtha Chakraborty, John Lydeard
  • Patent number: 12161674
    Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: December 10, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ewelina Morawa, Tirtha Chakraborty, Ante Sven Lundberg, Tony Ho, Laura Sandler, Brenda Eustace, Jerome Rossert, Robert Kauffman
  • Publication number: 20240384304
    Abstract: Provided herein are oligonucleotides comprising a first region that is complementary to a targeting domain of a gRNA and a second region that is complementary to a CRISPR RNA (crRNA) sequence for a CRISPR/Cas nuclease, wherein the oligonucleotide reduces genomic editing at a target sequence complementary to the targeting domain of the gRNA. Also provided herein are methods involving contacting a gRNA, a CRISPR/Cas nuclease, a complex comprising the same, or a cell comprising any thereof with such oligonucleotides.
    Type: Application
    Filed: July 6, 2022
    Publication date: November 21, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Dane Hazelbaker, Elizabeth Paik, Michael Pettiglio, Tirtha Chakraborty
  • Publication number: 20240352481
    Abstract: Provided herein are IL-2 reporter systems comprising nucleic acid constructs comprising a nucleotide sequence encoding a reporter molecule operably linked to a minimal nuclear factor of activated T cells (NFAT)-responsive promoter. Also provided herein are vectors, cells, and cell lines comprising such nucleic acids. Also provided herein are methods of making and using such cells, for example to measure the ability of a chimeric antigen receptor (CAR) to induce nuclear factor of activated T cells (NFAT)-signaling in a cell.
    Type: Application
    Filed: July 29, 2022
    Publication date: October 24, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Brikena Gjeci, Tirtha Chakraborty, Julian Scherer
  • Publication number: 20240344058
    Abstract: Provided herein are gRNA comprising a targeting domain that targets BCMA, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the BCMA gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: October 29, 2021
    Publication date: October 17, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Julia Etchin, Tirtha Chakraborty
  • Publication number: 20240226339
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting modulating or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: March 21, 2024
    Publication date: July 11, 2024
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-Ching Lin, Bibhu Prasad Mishra, Elizabeth Paik, Andrew Kernytsky, Todd Douglass Borland
  • Patent number: 12023371
    Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 2, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan
  • Publication number: 20240041932
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD5, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD5 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 14, 2021
    Publication date: February 8, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Tirtha Chakraborty
  • Publication number: 20240033290
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD7, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD7 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 1, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Julia Etchin, Michael Pettiglio, Tirtha Chakraborty
  • Publication number: 20240000846
    Abstract: Aspects of the disclosure provide methods and compositions for treating a hematopoietic malignancy (e.g., acute myeloid leukemia). In some aspects, the disclosure provides methods of treatment using a population of genetically engineered CD33-deficient hematopoietic cells and a cytotoxic agent comprising an anti-CD33 antigen-binding domain.
    Type: Application
    Filed: October 27, 2021
    Publication date: January 4, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Christopher Slapak, Glen Raffel, Michelle Lin, John Lydeard, Tirtha Chakraborty
  • Publication number: 20230414755
    Abstract: The disclosure is directed to methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors, where the cells are mobilized lymphocytes.
    Type: Application
    Filed: November 12, 2021
    Publication date: December 28, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: Sadik Kassim, Julian Scherer, Giacomo Canesin, Tirtha Chakraborty
  • Publication number: 20230398219
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD38, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD38 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 14, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
  • Publication number: 20230364233
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD6, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD6 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 28, 2021
    Publication date: November 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
  • Publication number: 20230364146
    Abstract: Provided herein are gRNA comprising a targeting domain that targets CD30, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD30 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.
    Type: Application
    Filed: September 30, 2021
    Publication date: November 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty